Metabolic Liver Disease
Inventiva’s clinical research is centred on non-alcoholic steatohepatitis (NASH), with attention to adult patients affected by non-cirrhotic liver disease and fibrosis stages F2 and F3. The sponsor’s studies reflect a focused interest in liver histology and disease modification in chronic metabolic liver disorders.
- NASH
- Non-cirrhotic liver fibrosis
- Liver histology
Clinical activity in this area is supported across multiple international research sites, with ongoing recruitment in several countries.
Fibrosis Resolution
The sponsor is involved in research addressing fibrosis improvement and NASH resolution, with a therapeutic emphasis on reversing structural liver damage and assessing changes in fibrotic progression. This includes evaluation of outcomes relevant to hepatic tissue repair and disease control.
- Fibrosis improvement
- NASH resolution
- Hepatic tissue repair
These research interests align with a clinical focus on advanced liver pathology in patients with progressive metabolic injury.
Long-Term Safety in Chronic Therapy
Inventiva also supports studies examining the safety of lanifibranor over extended treatment periods in adults with NASH. The therapeutic interest extends to maintaining tolerability during prolonged management of a chronic liver condition.
- Lanifibranor safety
- Extended treatment exposure
- Chronic disease management
This area reflects a sustained focus on therapies intended for ongoing use in patients requiring long-term care.
Bioequivalence and Pharmaceutical Development
Beyond disease-specific work, the sponsor is involved in bioequivalence research related to lanifibranor, indicating interest in the pharmaceutical profile of the compound and its development as a therapeutic option. This area connects formulation and product comparability with the broader drug development programme.
- Bioequivalence
- Lanifibranor
- Drug development
The sponsor’s research portfolio therefore spans both clinical efficacy in NASH and supporting pharmaceutical evaluation.
